Kees Hovingh

6.7k total citations
21 papers, 409 citations indexed

About

Kees Hovingh is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Cancer Research. According to data from OpenAlex, Kees Hovingh has authored 21 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Surgery, 6 papers in Cardiology and Cardiovascular Medicine and 6 papers in Cancer Research. Recurrent topics in Kees Hovingh's work include Lipoproteins and Cardiovascular Health (12 papers), Cancer, Lipids, and Metabolism (5 papers) and Cholesterol and Lipid Metabolism (4 papers). Kees Hovingh is often cited by papers focused on Lipoproteins and Cardiovascular Health (12 papers), Cancer, Lipids, and Metabolism (5 papers) and Cholesterol and Lipid Metabolism (4 papers). Kees Hovingh collaborates with scholars based in Netherlands, United States and Canada. Kees Hovingh's co-authors include Simon Jones, Ornella Guardamagna, Devaki Nair, Emilio Ros, Handrean Soran, John Hamilton, S. Calandra, Stefano Bertolini, Željko Reiner and John J.P. Kastelein and has published in prestigious journals such as PLoS ONE, Circulation Research and Arteriosclerosis Thrombosis and Vascular Biology.

In The Last Decade

Kees Hovingh

18 papers receiving 401 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kees Hovingh Netherlands 9 149 122 109 102 87 21 409
Lara Valiño‐Rivas Spain 14 62 0.4× 70 0.6× 34 0.3× 225 2.2× 44 0.5× 23 602
Sunil B. Kumaraswamy Sweden 3 155 1.0× 87 0.7× 64 0.6× 418 4.1× 85 1.0× 5 612
Antoinette Bugyei‐Twum Canada 9 69 0.5× 36 0.3× 158 1.4× 195 1.9× 57 0.7× 11 416
Gabin Sihn Germany 8 40 0.3× 30 0.2× 149 1.4× 193 1.9× 120 1.4× 10 399
Davoud Mohtat United States 5 77 0.5× 48 0.4× 28 0.3× 412 4.0× 69 0.8× 6 778
Bozena Krolewski United States 12 58 0.4× 49 0.4× 43 0.4× 200 2.0× 85 1.0× 26 468
Giampiero Piras Italy 7 54 0.4× 39 0.3× 58 0.5× 107 1.0× 103 1.2× 9 444
G. Fini Italy 13 83 0.6× 147 1.2× 99 0.9× 166 1.6× 85 1.0× 30 536
Federico Bigazzi Italy 12 256 1.7× 45 0.4× 150 1.4× 105 1.0× 90 1.0× 47 462
Marcus D. Skaflen United States 13 224 1.5× 66 0.5× 73 0.7× 284 2.8× 53 0.6× 13 665

Countries citing papers authored by Kees Hovingh

Since Specialization
Citations

This map shows the geographic impact of Kees Hovingh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kees Hovingh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kees Hovingh more than expected).

Fields of papers citing papers by Kees Hovingh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kees Hovingh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kees Hovingh. The network helps show where Kees Hovingh may publish in the future.

Co-authorship network of co-authors of Kees Hovingh

This figure shows the co-authorship network connecting the top 25 collaborators of Kees Hovingh. A scholar is included among the top collaborators of Kees Hovingh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kees Hovingh. Kees Hovingh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kosiborod, Mikhail, Steen Z. Abildstrøm, Barry A. Borlaug, et al.. (2023). Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. JACC Heart Failure. 11(8). 1000–1010. 49 indexed citations
2.
Hemphill, Linda, Anne C. Goldberg, Kees Hovingh, Jerome D. Cohen, & Dean G. Karalis. (2020). Recognition and Treatment of Homozygous Familial Hypercholesterolemia by Primary Care Physicians: a Survey from the National Lipid Association. Journal of General Internal Medicine. 35(7). 2225–2227. 4 indexed citations
3.
4.
Ronde, Maurice W.J. de, et al.. (2019). Sudden cardiac death in families with premature cardiovascular disease. Heart. 106(3). heartjnl–2019. 1 indexed citations
5.
Ivanov, Stoyan, Nemanja Vujić, Madalina Duta-Mare, et al.. (2019). Lysosomal Cholesterol Hydrolysis Couples Efferocytosis To Anti-Inflammatory Oxysterol Production. Atherosclerosis. 287. e77–e77. 2 indexed citations
6.
Hartgers, Merel L., et al.. (2019). Variants In Signal Transducing Adaptor Family Member 1 (Stap1) Do Not Affect Ldl-Cholesterol. Atherosclerosis. 287. e79–e79. 1 indexed citations
7.
Oldoni, Federico, Julian C. van Capelleveen, Justina C. Wolters, et al.. (2018). Naturally Occurring Variants in LRP1 (Low-Density Lipoprotein Receptor–Related Protein 1) Affect HDL (High-Density Lipoprotein) Metabolism Through ABCA1 (ATP-Binding Cassette A1) and SR-B1 (Scavenger Receptor Class B Type 1) in Humans. Arteriosclerosis Thrombosis and Vascular Biology. 38(7). 1440–1453. 14 indexed citations
8.
Gaudet, Daniel, Daniel A. Gipe, Kees Hovingh, et al.. (2017). Safety and Efficacy of Evinacumab, A Monoclonal Antibody to ANGPTL3, In Homozygous Familial Hypercholesterolemia. Journal of clinical lipidology. 11(3). 837–838. 3 indexed citations
9.
10.
Raal, Frederick J., et al.. (2017). The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. European Journal of Preventive Cardiology. 24(17). 1843–1850. 24 indexed citations
11.
Thedrez, Aurélie, Barbara Sjouke, Alexis F. Guédon, et al.. (2016). Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report. Arteriosclerosis Thrombosis and Vascular Biology. 36(8). 1647–1650. 19 indexed citations
12.
Ljunggren, Stefan, Johannes H.M. Levels, Kees Hovingh, et al.. (2015). Lipoprotein profiles in human heterozygote carriers of a functional mutation P297S in scavenger receptor class B1. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1851(12). 1587–1595. 15 indexed citations
13.
Chai, Chen, Federico Torta, Chung Hwee Thiam, et al.. (2015). Mutations in ABCA8 underlie reduced plasma high density cholesterol levels in humans. Atherosclerosis. 241(1). e23–e24. 1 indexed citations
14.
Reiner, Željko, Ornella Guardamagna, Devaki Nair, et al.. (2014). Lysosomal acid lipase deficiency – An under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis. 235(1). 21–30. 202 indexed citations
15.
Guardamagna, Ornella, Devaki Nair, Kees Hovingh, et al.. (2014). Lysosomal acid lipase deficiency e An under-recognized cause of dyslipidaemia and liver dysfunction.
16.
Hovingh, Kees, Joost Besseling, & John J.P. Kastelein. (2013). Efficacy and safety of mipomersen sodium (Kynamro). Expert Opinion on Drug Safety. 12(4). 569–579. 24 indexed citations
17.
Singaraja, Roshni R., Kees Hovingh, Linhua Zhang, et al.. (2013). Abstract 155: Mutations In ABCA8 Result In HDL Deficiency And Cholesterol Efflux Defects. Circulation Research. 113(suppl_1). 1 indexed citations
18.
Ljunggren, Stefan, Johannes H.M. Levels, Maria V. Turkina, et al.. (2013). ApoA‐I mutations, L202P and K131del, in HDL from heterozygotes with low HDL‐C. PROTEOMICS - CLINICAL APPLICATIONS. 8(3-4). 241–250. 5 indexed citations
19.
Sivapalaratnam, Suthesh, Hanneke Basart, Nicholas A. Watkins, et al.. (2012). Monocyte Gene Expression Signature of Patients with Early Onset Coronary Artery Disease. PLoS ONE. 7(2). e32166–e32166. 26 indexed citations
20.
Hovingh, Kees & Marcel M. Levi. (2008). Bleeding complications in patients on anticoagulants who would have been disqualified for clinical trials. Thrombosis and Haemostasis. 100(12). 1047–1051. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lara Valiño‐Rivas Breakdown of academic impact, for papers by Sunil B. Kumaraswamy Breakdown of academic impact, for papers by Antoinette Bugyei‐Twum Breakdown of academic impact, for papers by Gabin Sihn Breakdown of academic impact, for papers by Davoud Mohtat Breakdown of academic impact, for papers by Bozena Krolewski Breakdown of academic impact, for papers by Giampiero Piras Breakdown of academic impact, for papers by G. Fini Breakdown of academic impact, for papers by Federico Bigazzi Breakdown of academic impact, for papers by Marcus D. Skaflen
Rankless by CCL
2026